Skip to main content
Premium Trial:

Request an Annual Quote

Siemens Healthcare Establishes MDx Research Facility in Germany

NEW YORK (GenomeWeb News) – Siemens Healthcare this week said that it has established a new research lab focused on molecular diagnostics in Cologne, Germany.
 
The medical imaging and diagnostics giant said that the initial focus of the research labs will be on breast cancer diagnostics. It said that it would employ biochips in developing the tests, but did not say whether the chips were developed internally or are based on another company’s technology.
 
Siemens noted that it currently has 40 employees in Cologne developing molecular diagnostic tests for cancer.
 
“Viewed from the perspective of Siemens, a medicine that is more strongly based on molecular medical and knowledge-based techniques will be able to make important long-term contributions toward improving the quality and increasing the efficiency of healthcare,” Donal Quinn, CEO of the Diagnostics Division of Siemens Healthcare, said in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.